Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-45
SponsorPeking Union Medical College Hospital

About this trial

The goal of this clinical trial is to learn if administering ondansetron prior to esophagogastroduodenoscopy (EGD) can alleviate the gagging reflex, nausea and vomiting in Chinese patients undergoing unsedated diagnostic EGD. The main questions it aims to answer are:

Does taking ondansetron prior to EGD reduce the discomfort of patients during the endoscopic process? Does taking ondansetron prior to EGD reduce the intensity of patient gagging and nausea, and the incidence of vomiting ? Researchers will compare premedication of oral ondasetron and topical pharyngeal anesthesia (dyclonine hydrochloride mucilage) with topical pharyngeal anesthesia only to see if ondansetron can exert the above-mentioned effects.

Participants will be treated with one of the following regimens according to the randomization result:

* Oral ondansetron of 8 mg 2 hours prior to endoscopic process and dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to endoscopic process; * dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to endoscopic process.

After the endoscopic process is finished, patients will be asked to fill in a questionnaire that contains the following items, all measured by NRS 0-10:

* Overall discomfort; * Intensity of gagging; * Willingness to undergo unsedated EGD again if indicated.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients indicated for diagnostic EGD: patients with symptoms in which EGD may influence di-agnosis and/or disease management, including dysphagia, odynophagia, esophageal refluc symptoms, persistent vomiting, gastrointestinal bleeding, and other upper gastrointestinal symptoms.

Signing a written informed consent.

Disqualifiers

Contraindications for esophagogastroduodenoscopy.

History of upper gastrointestinal tract surgery.

Severe diseases of the heart, kidney, respiratory system, central nervous system, and hematopoietic system.

Pregnancy.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Oral ondansetron and dyclonine hydrochloride mucilage

    Drug

    Patients will take 8 mg oral ondansetron 2 hours prior to EGD process in addition to dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to EGD process.

  • Dyclonine hydrochloride mucilage

    Drug

    Patients will be instructed to gurgle 10 mL of dyclonine chloride mucilage (0.01 g/mL) and gurgle for 1 minute 15 minutes prior to endoscopic process.

Treatment groups

260 Participants
are divided into 2 treatment groups
Group A: oral ondansetron and dyclonine hydrochloride mucilageExperimental treatment 1 intervention
Group B: dyclonine hydrochloride mucilage onlyOther 1 intervention

Trial outcomes

Primary outcomes

1

Overall discomfort of patients

measured by NRS 0-10 (0 no discomfort, 10 as uncomfortable as can be), in a questionnaire given to patients after the endoscopic process is finished

Time frame
from the start of the endoscopic process to the end of the endoscopic process

Secondary outcomes

1

Intensity of gagging evaluated by patients

measured by NRS 0-10 (0 none, 10 extremely strong), in a questionnaire given to patients after the endoscopic process is finished

Time frame
from the start of the endoscopic process to the end of the endoscopic process
2

Intensity of patient gagging evaluated by endoscopist

measured by NRS 0-10, (0 none, 10 extremely strong) in a questionnaire given to endoscopists after the endoscopic process is finished

Time frame
from the start of the endoscopic process to the end of the endoscopic process
3

Patient willingness to undergo unsedated EGD again

the willingness of patients to undergo unsedated EGD in the same method again, assessed by NRS 0-10 (0, not willing at all; 10 completely willing).

Time frame
at the end of the endoscopic process
4

Endoscopist satisfaction

satisfaction of endoscopist in this process, assessed by NRS 0-10 (0, not satisfied at all; 10 very satisfied).

Time frame
from the start to the end of the endoscopic process

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: